MA33430B1 - Dérivés de pyrazinooxazépine - Google Patents

Dérivés de pyrazinooxazépine

Info

Publication number
MA33430B1
MA33430B1 MA34535A MA34535A MA33430B1 MA 33430 B1 MA33430 B1 MA 33430B1 MA 34535 A MA34535 A MA 34535A MA 34535 A MA34535 A MA 34535A MA 33430 B1 MA33430 B1 MA 33430B1
Authority
MA
Morocco
Prior art keywords
pyrazinoxazepine
derivatives
compound
serotonin
obesity
Prior art date
Application number
MA34535A
Other languages
Arabic (ar)
English (en)
Inventor
Shigekazu Sasaki
Tomokazu Kusumoto
Izumi Nomura
Hironobu Maezaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA33430B1 publication Critical patent/MA33430B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION PORTE SUR UN COMPOSÉ AYANT UNE ACTION ACTIVANT LE RÉCEPTEUR 5-HT2C DE LA SÉROTONINE, UTILE POUR DES ÉTATS CONCERNANT LE TRACTUS URINAIRE INFÉRIEUR, L'OBÉSITÉ ET LE CANCER. L'INVENTION PORTE SUR UN COMPOSÉ REPRÉSENTÉ PAR LA FORMULE (IO) : DANS LAQUELLE CHAQUE SYMBOLE EST TEL QUE DÉFINI DANS LA DESCRIPTION, OU UN SEL DE CELUI-CI.
MA34535A 2009-06-15 2010-06-14 Dérivés de pyrazinooxazépine MA33430B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009142673 2009-06-15
PCT/JP2010/060408 WO2010147226A1 (fr) 2009-06-15 2010-06-14 Dérivés de pyrazinooxazépine

Publications (1)

Publication Number Publication Date
MA33430B1 true MA33430B1 (fr) 2012-07-03

Family

ID=42561089

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34535A MA33430B1 (fr) 2009-06-15 2010-06-14 Dérivés de pyrazinooxazépine

Country Status (40)

Country Link
US (4) US8318722B2 (fr)
EP (1) EP2442870B1 (fr)
JP (2) JP5579262B2 (fr)
KR (1) KR101768234B1 (fr)
CN (1) CN102458579B (fr)
AR (1) AR077094A1 (fr)
AU (1) AU2010260847B2 (fr)
BR (1) BRPI1011502A2 (fr)
CA (1) CA2765239C (fr)
CL (1) CL2011003154A1 (fr)
CO (1) CO6491037A2 (fr)
CR (1) CR20120021A (fr)
CY (1) CY1115483T1 (fr)
DK (1) DK2442870T3 (fr)
DO (1) DOP2011000393A (fr)
EA (1) EA021079B1 (fr)
EC (1) ECSP12011603A (fr)
ES (1) ES2480275T3 (fr)
GE (1) GEP20146168B (fr)
HR (1) HRP20140589T1 (fr)
IL (1) IL216761A (fr)
JO (1) JO3087B1 (fr)
MA (1) MA33430B1 (fr)
ME (1) ME01835B (fr)
MX (1) MX2011013081A (fr)
MY (1) MY157497A (fr)
NZ (1) NZ597507A (fr)
PE (1) PE20121049A1 (fr)
PL (1) PL2442870T3 (fr)
PT (1) PT2442870E (fr)
RS (1) RS53414B (fr)
SG (1) SG176696A1 (fr)
SI (1) SI2442870T1 (fr)
SM (1) SMT201400080B (fr)
TN (1) TN2011000630A1 (fr)
TW (2) TWI542592B (fr)
UA (1) UA108357C2 (fr)
UY (1) UY32707A (fr)
WO (1) WO2010147226A1 (fr)
ZA (1) ZA201109370B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727585A1 (fr) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited Méthode de dépistage in-vivo
EA021079B1 (ru) * 2009-06-15 2015-03-31 Такеда Фармасьютикал Компани Лимитед Производные пиразинооксазепина
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
JP2014201578A (ja) * 2013-04-09 2014-10-27 武田薬品工業株式会社 線維筋痛症治療剤
JP2014214132A (ja) * 2013-04-26 2014-11-17 武田薬品工業株式会社 ニコチン依存症の予防・治療剤
WO2015066344A1 (fr) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation
WO2017026538A1 (fr) 2015-08-07 2017-02-16 Takeda Pharmaceutical Company Limited Procédé de production de pyrazine
WO2017111178A1 (fr) 2015-12-24 2017-06-29 Takeda Pharmaceutical Company Limited Préparation solide
US9985579B2 (en) 2016-04-12 2018-05-29 Preformed Line Products Co. Mounting assembly for mounting a solar panel
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
NZ525699A (en) 2000-11-20 2005-03-24 Biovitrum Ab Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor
AU2002314744A1 (en) 2001-04-17 2002-10-28 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
JP4460450B2 (ja) 2002-06-19 2010-05-12 ビオヴィトルム・アクチボラゲット（プブリクト） 新規化合物、その使用および製造法
SI1645558T1 (sl) 2002-06-19 2008-10-31 Biovitrum Ab Publ Piperazinilpirazini kot modulatorji serotonin 5-HT2C receptorja
US7625887B2 (en) 2003-01-28 2009-12-01 Takeda Pharmaceutical Company Limited Receptor agonists
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
PL2332921T3 (pl) 2003-06-17 2016-08-31 Arena Pharm Inc Chlorowodorek 8-chloro-1-metylo-2,3,4,5-tetrahydro-1H-3-benzazepiny
CN1805938B (zh) 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
JP2006056881A (ja) 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
CN101253153A (zh) 2005-09-01 2008-08-27 伊莱利利公司 作为5－HT<sub>2c</sub>受体激动剂的6－取代的2,3,4,5－四氢－1H－苯并[d]氮杂䓬
FR2895259B1 (fr) 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires
EP2727585A1 (fr) * 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited Méthode de dépistage in-vivo
EP2123644B1 (fr) * 2007-03-07 2014-12-17 Takeda Pharmaceutical Company Limited Dérivés de benzodiazépine et utilisation de ces derniers
US20090062253A1 (en) 2007-08-31 2009-03-05 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
EP2789338A3 (fr) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Dérivé de pyridine condensé et son utilisation
WO2009063993A1 (fr) * 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited Dérivé de pyridine fusionné et son utilisation
WO2009063991A1 (fr) * 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited Dérivé de pyridooxazépine et son utilisation
EA021079B1 (ru) * 2009-06-15 2015-03-31 Такеда Фармасьютикал Компани Лимитед Производные пиразинооксазепина
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor

Also Published As

Publication number Publication date
JO3087B1 (ar) 2017-03-15
CL2011003154A1 (es) 2012-06-15
RS53414B (sr) 2014-12-31
US8314088B2 (en) 2012-11-20
US20100317651A1 (en) 2010-12-16
CY1115483T1 (el) 2017-01-04
BRPI1011502A2 (pt) 2016-03-22
US9115139B2 (en) 2015-08-25
EP2442870A1 (fr) 2012-04-25
ZA201109370B (en) 2012-10-31
UA108357C2 (xx) 2015-04-27
MX2011013081A (es) 2012-01-20
JP2012107032A (ja) 2012-06-07
EA021079B1 (ru) 2015-03-31
AR077094A1 (es) 2011-08-03
AU2010260847B2 (en) 2016-11-24
CN102458579B (zh) 2014-11-05
ECSP12011603A (es) 2012-03-30
TW201109338A (en) 2011-03-16
US20120135979A1 (en) 2012-05-31
DK2442870T3 (da) 2014-06-30
TN2011000630A1 (en) 2013-05-24
ME01835B (me) 2014-12-20
JP2012530051A (ja) 2012-11-29
HK1169623A1 (en) 2013-02-01
GEP20146168B (en) 2014-09-25
SMT201400080B (it) 2014-09-08
CN102458579A (zh) 2012-05-16
SI2442870T1 (sl) 2014-07-31
CA2765239A1 (fr) 2010-12-23
KR20120034734A (ko) 2012-04-12
WO2010147226A1 (fr) 2010-12-23
TW201529584A (zh) 2015-08-01
JP5579262B2 (ja) 2014-08-27
MY157497A (en) 2016-06-15
TWI542592B (zh) 2016-07-21
US8324201B2 (en) 2012-12-04
PT2442870E (pt) 2014-07-16
CO6491037A2 (es) 2012-07-31
HRP20140589T1 (hr) 2014-08-01
EP2442870B1 (fr) 2014-04-16
PE20121049A1 (es) 2012-08-22
IL216761A0 (en) 2012-02-29
UY32707A (es) 2011-01-31
CA2765239C (fr) 2018-08-07
PL2442870T3 (pl) 2014-12-31
DOP2011000393A (es) 2012-02-15
JP5579203B2 (ja) 2014-08-27
KR101768234B1 (ko) 2017-08-14
US20110282054A1 (en) 2011-11-17
NZ597507A (en) 2013-09-27
US8318722B2 (en) 2012-11-27
IL216761A (en) 2016-03-31
CR20120021A (es) 2012-03-06
EA201270017A1 (ru) 2012-07-30
US20110288291A1 (en) 2011-11-24
SG176696A1 (en) 2012-01-30
AU2010260847A1 (en) 2012-01-19
ES2480275T3 (es) 2014-07-25

Similar Documents

Publication Publication Date Title
MA33430B1 (fr) Dérivés de pyrazinooxazépine
MA33363B1 (fr) Antagonistes de la voie de signalisation hedgehog a base de phtalazine disubstituee
MA31189B1 (fr) Composés à cycles fusionnés utiles en tant qu&#39;agonistes partiels de ppar-gamma
MA33224B1 (fr) Derives de proline comme inhibiteurs de la cathepsine
MA34713B1 (fr) Compose bicyclique
MA33637B1 (fr) Cristaux
EA201000113A1 (ru) Пиразольные соединения
MA34509B1 (fr) Composé hétérocyclique et son utilisation
MA31358B1 (fr) Méthodes de traitement du cancer à l&#39;aide d&#39;inhibiteurs de pi3k alpha à base de pyridopyrimidinone
EA201070428A1 (ru) Ингибиторы hdac
SG163585A1 (en) Melanocortin receptor ligands
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
EA201071229A1 (ru) Производные иминопиридина и их применение
EP2051967A4 (fr) Dérivés de benzimidazole utilisables pour le traitement des troubles liés au récepteur des vallinoïdes trpv1
MA33569B1 (fr) Ligands sigma pour la prevention ou le traitement de la douleur induite par la chimiotherapie
MA32985B1 (fr) Nouveaux microbiocides
MA39688A (fr) Composés hétéroaryle pour le traitement de maladies ophtalmiques
EP2173364A4 (fr) Traitement ou prévention d&#39;une infection par un rotavirus
MA34982B1 (fr) Synthese de derives de 2-carboxamidocycloaminouree
MA32997B1 (fr) Macrolide anti-inflammatoire
MA30341B1 (fr) Dérivés de benzimidazole
MA32482B1 (fr) Utilisation d&#39;inhibiteurs de hdac pour le traitement de la maladie de hodgkin
MX2009005249A (es) Compuestos organicos.
MX2009006507A (es) Nueva combinacion para usarse en el tratamiento de trastornos inflamatorios.
TN2011000254A1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines